
Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.
head of the Department of Clinical Researches at Todua Clinic in Tbilisi, Georgia

Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.

Cemiplimab demonstrated a 56% overall survival rate, making it a potential option for physicians to use for treating non–small cell lung cancer (NSCLC).

Cemiplimab plus chemotherapy was found to be consistently effective in treating non-small cell lung cancer (NSCLC) and held up in the EMPOWER-Lung 3 trial.

259 Prospect Plains Rd, Bldg H
 Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
